Close Menu

LifeCodexx

Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.

Indian preventative healthcare provider LifeCell will offer the test under its BabyShield brand.

The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology.

The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.

LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.

The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.

The company's PrenaTest BioIT analysis software is now also cleared for use with a new methylation-specific qPCR assay for the detection of fetal trisomy 21.

Following this agreement, LifeCodexx's PrenaTest is now available in more than 40 countries throughout Europe and the Middle East. 

Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.

The tech transfers are aided by LifeCodexx's PrenaBoxx NIPT data analysis solution, which runs locally and can analyze both NGS and qPCR data.

Pages

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.